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Abstract
Background: Photoreceptor cells containing melanopsin play a role in the phase-shifting effects of short-wavelength
light. In a previous study, we compared the standard light treatment (SLT) of SAD with treatment using short-
wavelength blue-enriched white light (BLT). Both treatments used the same illuminance (10 000 lux) and were equally
highly effective. It is still possible, however, that neither the newly-discovered photoreceptor cells, nor the biological
clock play a major role in the therapeutic effects of light on SAD. Alternatively, these effects may at least be partly
mediated by these receptor cells, which may have become saturated as a result of the high illuminances used in the
therapy. This randomized controlled study compares the effects of low-intensity BLT to those of high-intensity SLT.
Method: In a 22-day design, 22 patients suffering from a major depression with a seasonal pattern (SAD) were
given light treatment (10 000 lux) for two weeks on workdays. Subjects were randomly assigned to either of the
two conditions, with gender and age evenly distributed over the groups. Light treatment either consisted of 30
minutes SLT (5000°K) with the EnergyLight
® (Philips, Consumer Lifestyle) with a vertical illuminance of 10 000 lux at
eye position or BLT (17 000°K) with a vertical illuminance of 750 lux using a prototype of the EnergyLight
® which
emitted a higher proportion of short-wavelengths. All participants completed questionnaires concerning mood,
activation and sleep quality on a daily basis. Mood and energy levels were also assessed on a weekly basis by
means of the SIGH-SAD and other assessment tools.
Results: On day 22, SIGH-SAD ratings were significantly lower than on day 1 (SLT 65.2% and BLT 76.4%). On the
basis of all assessments no statistically significant differences were found between the two conditions.
Conclusion: With sample size being small, conclusions can only be preliminary. Both treatment conditions were
found to be highly effective. The therapeutic effects of low-intensity blue-enriched light were comparable to those
of the standard light treatment. Saturation effects may play a role, even with a light intensity of 750 lux. The
therapeutic effects of blue-enriched white light in the treatment of SAD at illuminances as low as 750 lux help
bring light treatment for SAD within reach of standard workplace and educational lighting systems.
Background
Exposure to bright light has proved to be a very effective
treatment for seasonal affective disorder (SAD), winter
type, for over 25 years now [1-3]. Ever since light treat-
ment was first used, light fixtures and treatment models
have improved and have followed science-based innova-
tions. A recent scientific development has been the dis-
covery of a novel photoreceptor, melanopsin, within the
basal ganglia of the retina [4-6]. This new photoreceptor
plays a major role in regulating the biological clock [5,7]
and is also involved in pupillary constriction [8]. It influ-
ences the circadian system and is the most sensitive to
light with a wavelength of about 480 nm (blue light)
[9-11]. According to the phase-shift hypothesis, the
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SAD and the working mechanisms of light treatment
[12]. According to this hypothesis, blue light is thought
to be more powerful in the treatment of SAD than light
of other wavelengths. In the treatment of SAD, exposure
to blue narrow-band light with an intensity of 398 lux
was in fact, found to be superior to dim red-light ther-
apy of 23 lux [13]. Equally, narrow-band blue light of a
lower intensity (176 lux) was found to be superior to
narrow-band red light of 201 lux [14].
In a previous study, however, we failed to find any dif-
ferences in treatment outcome after exposure to stan-
dard light treatment (SLT) and blue-enriched light
treatment (BLT) of identical intensities. A possible
explanation of this result may be that the maximum
(saturated) response to light treatment occurs at the
illuminance (~10000 lux) used in the comparison. Add-
ing more short-wavelength light can not increase this
response any further [15]. When equating the short
wavelength (424-532 nm) photon density at lower illu-
minances, blue monochromatic light of a modest photo-
pic intensity (98 lux) was equally effective in treating
SAD as white light of 711 lux [16].
This suggests that low-intensity light treatment, either
by blue light alone, or by blue-enriched white light may
be just as effective as the high-intensity lights used in
the SLT devices. In this study, we compared the effects
of the treatment of SAD after exposure to low-intensity
BLT (750 lux) to those after exposure to high-intensity
SLT (10000 lux).
Apart from a depressed mood, lack of energy and
decreased levels of activity and sleep quality are well-
known symptoms in patients suffering from SAD [1].
We therefore assessed the effects on mood, energy, dif-
ferent aspects of activation, and sleep quality in two
conditions.
Methods
Subjects
In the winter of 2008-2009 patients of the SAD outpatient
clinic of the University Medical Center Groningen, the
Netherlands were asked to participate in the study. Eight
patients were recruited by means of an advertisement in a
local newspaper. Potential participants were sent written
information and were invited for an intake interview at the
clinic in order to obtain a diagnosis by an experienced
clinical psychologist. The participants were informed
about the goal of the study: to investigate the effects of
low-intensity blue-enriched light treatment compared to
standard light treatment. If patients were suffering from
winter depression, they were given information about the
research project. After they had signed the informed con-
sent form, a screening visit was scheduled. Twenty-three
patients were included in the study. After a few days of
light treatment, one patient dropped out for reasons unre-
lated to her depression (concussion) and was excluded
from the study, leaving 22 patients. In the SLT condition 3
men and 8 women participated (mean age 39.9 yrs ± 12.7),
in the BLT condition this amounted to 2 men and 9
women (mean age 41.7 yrs ± 13.1).
The research protocol was approved by the Medical
Ethical Committee of the University Medical Center
Groningen.
Light therapy
Light treatment consisted of 2 weeks of SLT (correlated
colour temperature 5000°K, vertical illuminance at eye
position: 10 000 lux) with the EnergyLight (Philips Consu-
mer Lifestyle B.V., Drachten, The Netherlands) or 2 weeks
of BLT (correlated colour temperature 17 000°K) with a
vertical illuminance of 750 lux at eye position, adminis-
tered with an EnergyLight equipped with a special proto-
type lamp emitting white light with a high proportion of
short wavelengths with a correlated colour temperature of
17 000°K, as in the Philips ActiViva Active lamps. An
international standard for retinal blue-light hazard risk has
been defined to protect participants against retinal photo-
chemical injury from chronic blue-light exposure [17]. All
light conditions used in this study remain far below the
exposure limits as defined by this standard.
During light therapy, patients were sitting at equal dis-
tances (20 cm) from the EnergyLight in both conditions.
In Figure 1 the spectral-power distributions of the stan-
dard light and of the blue-enriched white light lamps
are shown.
Subjects came to the university hospital on 10 work-
days (days 4-8 and days 11-15 in the protocol) and were
given either 30 minutes SLT or BLT between 7:45 and
8:45 a.m. Treatment was given to one patient at a time,
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350 400 450 500 550 600 650 700 750
p
h
o
t
o
n
 
d
e
n
s
i
t
y
 
p
e
r
 
c
m
2
 
(
*
 
1
0
1
4
)
high colour lamps 17000°K
standard lamps 5000°K
0
2
4
6
8
10
12
Figure 1 Spectral-power distributions of the lamps used in the
standard EnergyLight
® (5000°K) and the specially-prepared
EnergyLight
® with blue-enriched white light (17 000°K).
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condition had an illuminance of 10 000 lux and a corre-
lated colour temperature of 5000 °K. In the 380-740 nm
wavelength band the SLT irradiance was 3207 microW/
cm2, with a total photon flux of 8.84 × 10
15 photons/
cm
2/s. The SLT irradiance within the 424-532 nm band
equals 1135 microW/cm2, with a photon flux of 2.7 ×
10
15 photons/cm
2/s. The BLT illuminance equals 750
Lux, with a correlated colour temperature of 17 000 °K.
The BLT irradiance within the 380-740 nm range equals
307 microW/cm2, with a total photon flux of 7.81 × 10
14
photons/cm
2/s. The BLT irradiance within the 424-532
nm band equals 168 microW/cm2, with a photon flux of
3.9 × 10
14 photons/cm
2/s.
Assessment and procedure
During the screening visit, patients were assessed by
means of a standardized structured interview, the Mini-
International Neuropsychiatric Interview (M.I.N.I) [18].
Subjects meeting the criteria of a major depressive dis-
order, seasonal pattern, winter type, according to the
DSM-IV-TR [19] were subsequently assessed by means
of the Structured Interview Guide for the Hamilton
Depression Rating Scale-Seasonal Affective Disorder, 24-
item version (SIGH-SAD) [20]. After that they were
asked to complete the Beck Depression Inventory-II-NL
(BDI-II-NL) [21], and a questionnaire aiming to evaluate
subjects’ expectations of the effects of light therapy. On
a 5-point scale this questionnaire rated both for SLT
and BLT whether subjects expected to benefit from the
therapy, whether they thought it was a logical treatment,
and whether they would recommend this therapy to a
friend. Subjects who met all inclusion criteria were ran-
domly assigned to one of the two conditions, with gen-
der and age distributed evenly over the groups. They
were not told which of the two conditions they were
going to participate in.
Each of the two conditions started at day 1 (Friday)
with a baseline measurement consisting of a SIGH-SAD
interview, the BDI-II-NL and a fatigue self-rating ques-
tionnaire (Short Fatigue Questionnaire, SFQ) [22]. The
SIGH-SAD interviewers were unaware of the experi-
mental conditions. The SIGH-SAD, the BDI-II-NL and
SFQ were repeated at day 8 (directly after the 5
th light
session), at day 15 (directly after the 10
th light session)
and at day 22 (1 week after light treatment had ended).
On day 22, an evaluation questionnaire was added to
check the outcome of subjects’ expectations on day 1.
Furthermore, subjects were asked which condition they
thought they had been treated in.
Starting at day 1, before 8.00 a.m. and at least 30 min-
utes after waking up subjects rated their mood and sleep
quality of the previous night on a daily basis using the
Adjective Mood Scale (AMS)[23,24] and the Groninger
Sleep Quality Scale (GSQS)[25,26]. Also, the following
four components of activation were measured, using the
Activation-Deactivation Check List (AD-ACL)[27]: Gen-
eral Activation (GA; i.e. energetic, vigorous, full of pep,
active, and lively), Deactivation-Sleep (DS; i.e. sleepy,
tired, drowsy, wide awake, and wakeful), High Activation
(HA; i.e. jittery, intense, fearful, clutched-up, and tense),
and General Deactivation (GD; i.e. placid, calm, at rest,
still and quiet). To describe their current feelings, sub-
jects were asked to rate these 20 adjectives on a 4-point
scale. The scores of the first 3 days on the daily question-
naires (before light treatment) were considered baseline.
Statistics
Baseline differences between the two conditions were
tested by means of t-tests (continuous outcomes) and
chi-square tests (dichotomous outcomes).
Effect sizes [28] were calculated for each condition.
These effect sizes reflect the differences between base-
line (day 1) and day 22. Results were based on the
weekly assessments of the two conditions and were
compared by means of repeated measures ANOVA.
This was done for the patients who had complete data
for these measures (n= 11 vs.11).
Linear Mixed Models were used to compare the two
conditions on the basis of the daily self-rating
questionnaires.
An advantage of these models is that all available data
can be used, including those of subjects with one or
more missing values. Consequently, in these analyses
data of all 22 subjects were used. Another advantage of
linear mixed models is that they allow for including ran-
dom effects; i.e. parameters are allowed to vary across
individuals. This may reveal heterogeneity in individual
growth curves. We used models with time, condition,
and the interaction between time and condition, with
the baseline score as a covariate (baseline score = mean
of the 3 pre-intervention scores). We fitted models with
the 22 days as the repeated measures and allowed the
slope to vary across individuals. Maximum likelihood
estimation was used. We compared models with differ-
ent variance-covariance matrices. Selection of the final
model was based on the Bayesian Information Criterion
(BIC; with lower values indicating better models). If the
random effect for slope was found to be non-significant,
this term was removed from the model (unless this
resulted in a higher value of the BIC criterion). Regres-
sion assumptions were checked by performing residual
diagnostics on the final models.
In a secondary analysis, we examined the potential
impact of the initial severity of the complaints on out-
come. To this end, we added the interaction baseline*-
time to the models. We also examined whether this
effect of baseline severity differed for the different
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time to the models, including all lower-order terms.
A responder was defined as a subject who improved at
least by 50%. Analyses were carried out using SPSS 17.
A two-tailed alpha level of 0.05 was used to determine
statistical significance.
Results
At the start of the experiment, there was no statistical
difference between the conditions with regard to gender,
age, and severity of depression or other complaints and
expectations about the effects of the light conditions as
measured by the self-rating questionnaires or standar-
dized interviews. All 22 participating subjects received
the intervention as intended.
Weekly assessments
The results of the weekly assessment procedures are
summarized in Table 1. Although subjects in both con-
ditions improved after exposure to light treatment, there
were no statistical differences between these
improvements.
In both conditions, depressive complaints decreased
during the 3-week period (Table 1, SIGH-SAD 24 items,
main effect “time” F(3,18) = 30.2, p < 0.001), with no
significant differences between conditions (main effect
“condition” F(1,20) = 0.012, ns) nor over time between
conditions (interaction effect “time*condition” F(3,60) =
0.95, ns). The same pattern emerged when the SIGH-
SAD was subdivided into “typical symptoms” (17-item
Hamilton rating, Table 1, main effect “time” F(3,18) =
28.2, p < 0.001; main effect “condition” F(1,20) = 0.00,
ns; interaction effect “time*condition” F(3,60) = 0.62, ns)
and “atypical items” (7 atypical items, Table 1, main
effect “time” F(3,18) = 18.84, p < 0.001; main effect
“condition” F(3,20) = 0.039, ns; interaction effect “time*-
condition” F(3,60) = 0.99, ns). Calculations based on the
BDI-II-NL scores showed similar results (main effect
“time” F(3,18) = 31.4, p < 0.001; main effect “condition”
F(1,20) = 0.78, ns; interaction effect “time*condition” F
(3,60) = 1.57, ns). Calculations based on the SFQ scores
point in the same direction (main effect “time” F(3,18) =
39.6, p < 0.001; main effect “condition” F(1,20) = 0.21,
ns; interaction effect “time*condition” F(3,60) = 1.42,
ns). Although the number of responders differs in the
two conditions (measurements based on the weekly rat-
ings), this difference was not statistically significant.
The evaluation questionnaire taken at day 22 shows
that participants of the blue-enriched white-light condi-
tion experienced the treatment as less comfortable than
participants of the standard bright-light treatment (F
(1,20) = 9.61, p = 0.006). After treatment, 2 subjects in
the SLT condition thought they had been treated in the
other condition, another 2 were unsure. In the BLT con-
dition 1 subject thought he had been treated in the
other condition and another one was unsure.
Daily questionnaires
As can be seen from Table 2, the results of the daily
self-rating questionnaires are in line with the results of
the weekly assessment procedures. There was no statisti-
cally significant difference in the way subjects improved.
The interaction time*condition was not significant in
any of the models. The time effect, on the other hand,
was significant in all models. Thus, mood, sleep quality
and energy levels improved in both conditions (Figure 2
and Table 2).
We also examined the influence of gender and age on
the outcomes. No interaction effects were found
between gender or age on the one hand and time or
time*condition on the other. Adjustments for gender
a n da g ed i dn o tc a u s ea n ys u b s t a n t i a lc h a n g e si nt h e
results either. Therefore, gender and age have not been
included in the final models.
Table 1 Weekly average depression scores (±SD)
Condition N Day 1 (SD) Day 8 (SD) Day 15 (SD) Day 22 (SD) Effect size d % Response Responder N
SIGH-SAD SLT 11 25.6 (6.3) 18.1 (8.0) 10.9 (4.4) 8.9 (6.8) 2.54 65.2 8
BLT 11 25.4 (6.9) 19 (6.0) 14 (10.1) 6 (4.0) 3.53 76.4 11
HRSD SLT 11 13.8 (4.6) 9.9 (4.3) 6.8 (3.0) 4.9 (3.9) 2.09 64.5 9
BLT 11 13,7 (5.4) 10,45(3.3) 7.8 (4,9) 3.4 (2.0) 2.53 75.2 10
ATYP SLT 11 11.8 (4.6) 8.2 (4.3) 4 (2.2) 4 (3.5) 1.91 66.1 8
BLT 11 11.6 (3.5) 8.5 (4.3) 6.2 (5.8) 2.6 (2.5) 2.96 77.6 10
BDI-II SLT 11 23 (5.3) 15.3 (8.1) 9.1 (6.4) 7.1 (6.4) 2.71 69.1 9
BLT 11 26.6 (10.8) 17.8 (11.7) 14.9 (11.4) 5.3 (3.8) 2.63 80.1 10
SFQ SLT 11 24.6 (2.0) 20.5 (7.0) 16.5 (6.0) 14.2 (5.5) 2.51 42.3 4
BLT 11 25.2 (2.8) 20.2 (6.2) 18.5 (7.5) 11 (4.5) 3.79 56.3 8
Cohen’s d effect size and response percentage from day 1 to day 22, as rated by the Hamilton Rating Scale for Depression (HRSD, 17 items), the scale that has
been adapted for seasonal symptoms SIGH-SAD (24 items), and the atypical symptoms separately ATYP (7 items), the score on the Beck Depression Inventory-II
and the Short Fatigue Questionnaire for each condition. SLT = standard light treatment; BLT= blue-enriched white-light treatment.
Responder = subject with an improvement of at least 50%.
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As can be seen from Table 2, in all models baseline
severity was related to outcome, with higher baseline
scores predicting higher overall follow-up scores. The
interaction between baseline scores and time was signifi-
cant in the models for Mood (p < 0.001), Sleep (p <
0.05), General Activation (p < 0.005), and General Deac-
tivation (p < 0.05). Consequently, baseline severity was
also related to change in symptoms over time. The
regression coefficients for the interaction effects had a
negative sign, which implies that higher baseline severity
predicted steeper slopes (more improvement).
The interaction condition*baseline*time was non-sig-
nificant in all models. This indicates that the effects of
baseline severity on outcome did not differ for the dif-
ferent conditions.
Discussion
The sample size in this study is very small, so results,
though promising, can only be very preliminary.
On all parameters, the effects of exposure to low-
intensity blue-enriched white light in the treatment of
SAD did not differ from the effects of exposure to stan-
dard bright-light treatment. In this study, participants
experienced blue-enriched white light as less comfortable
than the standard light condition. In a previous SAD
treatment study using blue-enriched white light of higher
intensities, no differences in appreciation emerged
between BLT and SLT [15].
However, in this study, participants indicated they
found the lower intensity blue-enriched white light
slightly less pleasant than the standard light condition,
a finding based on their answers on the evaluation
questionnaire. In the SLT group 63% (7 out of 11) of
the subjects rated the treatment as “rather pleasant” or
“very pleasant”. In the BLT group, treatment apprecia-
tion was slightly lower: 81% (9 out of 11) of the sub-
jects in the BLT group indicated the treatment to be
“neither pleasant, nor unpleasant”, “rather pleasant” or
“pleasant”.
T h i ss m a l ld i f f e r e n c ei na p p r e c i a t i o ni nt h ep r e s e n t
study is significant but must be interpreted within the
context of the relatively modest sample size.
Moreover, in office settings, illuminances of around
360 lux, blue-enriched white light (17 000 °K) have been
reported to improve subjective measures of irritability
and eye discomfort as compared to white light of 4000 °
K [29].
Exposure to low-intensity blue-enriched white light
(750 lux, 17 000 °K) is equally effective as standard full-
spectrum light treatment (10 000 lux, 5000 °K). It would
also have been interesting to make a direct comparison
between the effects of exposure to standard light at 750
lux and at 10 000 lux. However, data of other studies
indicate that higher-intensity light treatment leads to
larger improvements than light treatment with lower-
intensity light [2,30].
Results are in line with those of Anderson et al. [16],
who found that blue monochromatic low-intensity light
(98 lux) was equally effective in treating SAD as broad-
band white light at 711 lux with identical photon density
in the 424-532 nm range. The short wavelength photon
flux of these two conditions is highly comparable to the
BLT condition of the present study. The current find-
ings on exposure to low-intensity blue-enriched white
light are also in line with the results of studies in office
surroundings. It has been shown that sleep quality and
alertness improved when workers spent their day in an
office with blue-enriched white light with an intensity of
310.35 lux in the daytime instead of in the standard
white (4000 °K) office lighting conditions with a mean
intensity of 421.07 lux [29]. In a similar study, the stan-
dard room lighting had an intensity of 345 lux and was
compared to blue-enriched light with an intensity of 354
lux [31].
As the biological clock is known to be highly sensi-
tive to blue light, the phase-shift hypothesis suggests
that blue-enriched light is a more powerful treatment
for SAD than standard light. Although exposure to
Table 2 Daily self-rating questionnaires
Outcome Model Estimate P-value
Mood (AMS) Time -0.946 .000
condition 3.593 .283
time*condition -0.361 .152
baseline 0.619 .000
Sleep (GSQS) Time -0.154 .000
condition -0.054 .912
time*condition 0.008 .880
baseline 0.570 .000
Deactivation Sleep (AD-ACL) Time 0.058 .031
condition -0.045 .857
time*condition 0.028 .440
baseline 0.601 .000
General Activation (AD-ACL) Time 0.257 .000
condition -0.124 .894
time*condition 0.036 .606
baseline 0.472 .000
High Activation (AD-ACL) Time 0.090 .039
condition -0.220 .583
time*condition -0.020 .730
baseline 0.887 .000
General Deactivation (AD-ACL) Time 0.148 .001
condition -0.282 .471
time*condition -0.045 .440
baseline 0.813 .000
Results of regression analyses.
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leads to the same therapeutic results as exposure to
the standard bright-light treatment, this does not
necessarily indicates that blue or blue-enriched light
has a more powerful influence on the biological clock.
Studies by Smith et al. [32,33], have demonstrated
that, in a similar way, frequently used bright-light ther-
apy photon densities (4.2 vs. 4.9 10E15 photons/cm2/
s), blue-enriched white light (17 000 °K) does not
outperform standard white light (4100 °K) in phase-
advancing or phase-delaying effects. Interestingly, a
recent study indicated that for irradiances between
2E12 and 1.5E14 photons/cm2/s, blue (460 nm) light
does in fact outperform green light (555 nm) in phase-
shifting effects, whereas blue light yields smaller phase-
shifts than green light of identical photon density at
lower intensities (in the 2.5E11-2E12 photons/cm2/s
range) [34].
An alternative explanation for our finding that the
effects of blue-enriched light are not better than those
of standard light is the possibility that the blue wave-
lengths are not necessary for the therapeutic effects of
the treatment of SAD. Blue light plays a role in the
working mechanism of the biological clock, but the role
of the biological clock itself in the aetiology of SAD has
not been fully established yet [35-37].
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Figure 2 Scores on daily self-rating questionnaires assessing mood, sleep quality and four aspects of activation. For abbreviations: see
text. Higher scores on the AMS and GSQS mean more symptoms; higher scores on the AD-ACL mean fewer complaints.
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the similar responses to the two treatments could be
interpreted as placebo effects only. It is impossible to
create a real placebo condition for visible light treat-
ment, though. The few studies testing light therapy in
winter depressives using some kind of placebo condition
(for example a deactivated negative-ion generator)
revealed placebo effects that ranged from 21% to 41%
[38-40]. In a placebo-controlled study of extra-ocular
light treatment, we found a placebo response of 36%
[41]. In this latter study, participants visited the clinic in
the mornings for treatment, which was similar to the
visits in this study. The response rates in the current
study between 65% and 76% for remission are relatively
high compared to the placebo responses from the pla-
cebo-controlled studies, probably too high to be inter-
preted as placebo effects only, although we can not rule
out this possibility.
Conclusion
A l t h o u g ht h er o l eo fb l u el i g h ti nt h et r e a t m e n to f
SAD is still unclear, low-intensity blue-enriched white
light with an intensity of 750 lux is highly effective,
and equal to standard bright light at 10 000 lux, 5000 °
K. Monochromatic light of even lower intensity has
also shown to be effective in treating SAD [16]. At
present it is unknown at what light intensities the SAD
light-therapy response reaches saturation: this level
may be lower than the blue-enriched white-light set-
ting of 750 lux which is currently being used. There-
f o r e ,i ti sp o s s i b l et h a tb l u e - e n r i c h e dw h i t el i g h tw i t h
intensities below 750 lux still yields the same beneficial
effects. Further work is needed to investigate whether
an intensity threshold can be established for light
treatment for SAD and to find the lowest possible light
intensity that makes optimal treatment possible. As
indicated in the current findings, this lowest effective
intensity may depend on the spectral characteristics of
the light source. Further research is needed to find the
lowest optimal intensity for blue-enriched white light.
If blue-enriched white light with intensity below 750
lux is found to be effective in treating SAD, this may
make it possible to use this light in the regular room
lighting fixtures of patients,o re v e ni ng e n e r a ll i g h t i n g
systems used in workplaces and in educational and
healthcare settings.
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